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Cerebral palsy is a sporadic disorder with multiple likely aetiologies, but frequently considered to be caused by birth asphyxia.
Genetic investigations are rarely performed in patients with cerebral palsy and there is little proven evidence of genetic causes. As
part of a large project investigating children with ataxia, we identiﬁed four patients in our cohort with a diagnosis of ataxic
cerebral palsy. They were investigated using either targeted next generation sequencing or trio-based exome sequencing and were
found to have mutations in three different genes, KCNC3, ITPR1 and SPTBN2. All the mutations were de novo and associated
with increased paternal age. The mutations were shown to be pathogenic using a combination of bioinformatics analysis and
in vitro model systems. This work is the ﬁrst to report that the ataxic subtype of cerebral palsy can be caused by de novo
dominant point mutations, which explains the sporadic nature of these cases. We conclude that at least some subtypes of cerebral
palsy may be caused by de novo genetic mutations and patients with a clinical diagnosis of cerebral palsy should be genetically
investigated before causation is ascribed to perinatal asphyxia or other aetiologies.
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Introduction
The cerebral palsies are deﬁned as a group of permanent
disorders of movement and posture that are attributed to
non-progressive disturbances that occurred in the develop-
ing foetal or infant brain (Rosenbaum et al., 2007). They
are classiﬁed into clinical subtypes including spastic, dyski-
netic, dystonic and ataxic groups, but there may be add-
itional disturbances of cognition, communication and
behaviour. Some patients have brain imaging abnormal-
ities, such as focal infarction, brain malformations and
periventricular leukomalacia; however, not all children
with cerebral palsy have abnormal brain imaging and
determining the aetiology in such cases is particularly chal-
lenging (O’Shea, 2008; Reid et al., 2013).
Cerebral palsy is a common disorder affecting approxi-
mately 1 in 500 of the population in Western industrialized
nations (Oskoui et al., 2013), but despite being so
common, a proven cause is not always found. Although
recent studies have suggested that only 10–20% of cerebral
palsy cases can be explained by birth asphyxia (Nelson,
2003; Colver et al., 2014), there remains a widespread
belief that obstetric misadventure or even negligence is
the main cause of cerebral palsy, and many parents with
children diagnosed with cerebral palsy enquire about the
possibility of damage during the delivery process.
Obstetrics therefore has one of the highest rates of litiga-
tion within the medical profession and one of the highest
rates of outcome favouring the plaintiff (Jena et al., 2011).
Indeed, an internet search for the term ‘cerebral palsy’ pro-
vides dozens of legal services for claims of negligence and
as a result of this climate of litigation in developed coun-
tries the Caesarian section rate (and its complications) has
soared in the last 40 years (Nelson, 2003).
Despite major improvements in obstetric and perinatal
healthcare, the prevalence of cerebral palsy has remained
stubbornly stable (Nelson, 2003), suggesting that intrinsic
biological factors rather than extrinsic causes may be an
explanation. Genetic factors have been suggested in the
context of consanguinity (Moreno-De-Luca et al., 2011,
2012; Kruer et al., 2013), implicating autosomal recessive
mutations, but this still fails to explain the frequency of
sporadic cases without affected siblings. A recent study of
cerebral palsy found a higher rate of rare inherited copy-
number variations in cerebral palsy, but the functional sig-
niﬁcance of these variants was uncertain (McMichael et al.,
2013).
In the study presented here, four children were identiﬁed
who had a working diagnosis of sporadic ataxic cerebral
palsy and were found to have de novo mutations in three
different genes: KCNC3, which encodes a voltage-gated
potassium channel (Kv3.3); ITPR1, which encodes the re-
ceptor for inositol 1,4,5-trisphosphate (IP3R); and
SPTBN2, which encodes b-III spectrin. The likely patho-
genicity of the identiﬁed mutations was conﬁrmed by
using bioinformatics and electrophysiology. This study
has signiﬁcant implications for our understanding of cere-
bral palsy including its investigation, classiﬁcation and
aetiology.
Materials and methods
Genetic studies
Patients were recruited from throughout the UK and
Switzerland and consent for participation in the study was ob-
tained according to the Declaration of Helsinki (WMA, 1997)
and approved by the Central Oxford Research Ethics
Committee and the Research and Development Department of
the Oxford Radcliffe Hospitals NHS Trust, Oxford. All patients
or their parents provided written consent for the study. Ten
cases with a congenital cerebellar ataxia were analysed, the
ﬁrst using targeted capture and next generation sequencing,
and the remaining cases were analysed using exome sequencing.
Targeted sequencing in Case 1
The exonic and 25 base pairs (bp) intronic ﬂanking sequences
of 118 genes known to be associated with ataxia in humans or
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good candidate genes based on function were captured using
Agilent SureSelect enrichment and sequenced on the Illumina
GAII high-throughput sequencing platform as previously
described (Nemeth et al., 2013) (Supplementary material).
Sequence reads were aligned to the human reference genome
(GRCh37/hg19) and single-nucleotide variants (SNVs) and
small indels (insertion and deletions) were identiﬁed.
Sequence variants were annotated using the Ensembl Variant
Effect Predictor (VEP) tool (release 62, April 2011) (Flicek
et al., 2011). For each variant, the VEP predicts potential func-
tional consequences (e.g. non-synonymous coding, splice site,
intronic effects) and checks if the variant is already present in
the single nucleotide polymorphism database (dbSNP, Build
132) (Sherry et al., 2001). All variants were ﬁltered using a
previously reported algorithm (Shanks et al., 2013a) and
analysed using standard pathogenicity prediction programs
including PolyPhen-2 (Adzhubei et al., 2010), SIFT (Kumar
et al., 2009), MutPred (Li et al., 2009) and the mutation in-
terpretation software Alamut (http://www.interactive-biosoft
ware.com/). Sanger sequencing was used to conﬁrm variants
and parentage by analysing six informative single nucleotide
polymorphisms (SNPs) identiﬁed as part of the sequencing
analysis.
Next-generation exome sequencing
Instead of targeted capture and sequencing, exome capture was
performed in Cases 2–4 plus their parents (‘Trios 2–4’) using
the SureSelect Human All Exon kit v5 (Agilent Technologies)
and 100bp paired-end sequencing performed on the Illumina
HiSeq 2000 platform. At least 92% of the target region was
covered at 20. Reads were quality trimmed using the
FASTX-Toolkit v0.0.13 and then aligned to the 1000
Genomes version of the human reference genome
(human_g1k_v37) using the Burrows-Wheeler Aligner (BWA)
v0.7.5a. Likely PCR duplicates were removed using Picard
v1.106 and BAM ﬁles were processed using the Genome
Analysis Toolkit (GATK) v2.7.2 software. Single nucleotide
variants and indels were jointly called within each trio using
the GATK HaplotypeCaller and annotated using SnpEff v3.3
and SnpSift (Cingolani et al., 2012). De novo mutations were
selected using the Genome Analysis Toolkit Select Variants
walker according to previously described criteria (Epi4K
Consortium and Epilepsy Phenome/Genome Project, 2013)
(Allen et al., 2013). Two additional ﬁlters were imposed to
select for putative de novo variants present at 50.1% fre-
quency in 1000 Genomes individuals and the exome variant
server (http://evs.gs.washington.edu/EVS/) and predicted by
SnpEff to have a moderate or high impact. Variants were visu-
ally inspected using the Integrative Genomics Viewer (IGV)
(Thorvaldsdottir et al., 2013) and validated by Sanger sequen-
cing. Nucleotide conservation was estimated using the
Genomic Evolutionary Rate Proﬁling (GERP) (scores:
12.3 = least conserved to 6.17 = most conserved) (Cooper
et al., 2005) and PhyloP, which compares the probability of
observed substitutions under the hypothesis of neutral evolu-
tionary rate: positive scores suggest constraint (conservation)
(Pollard et al., 2010). Effects of amino acid changes were ana-
lysed using SIFT (probability of being pathogenic: 0 = highest;
1 = lowest) (Adzhubei et al., 2010) and PolyPhen-2 (probabil-
ity of being pathogenic: 0 = lowest; 1 = highest) (Sim et al.,
2012).
Confirmation of parentage using
exome sequencing data
For Cases 2–4, analysis of parentage was performed using
86 000 exonic Hapmap SNPs, which were genotyped from
the exome sequencing data using GATK HaplotypeCaller
(McKenna et al., 2010). The non-reference discordance
rate (NDR) was calculated by comparing genotype
calls for each pair-wise combination of individuals using
vcf-compare from the VCFtools suite of software (Danecek
et al., 2011). A heatmap depicting NDR values from all
combinations was plotted using the ggplot2 package
(Wickham, 2009) within the R statistical computing
environment (R Core Team (2014). R: A language and
environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/). Parent-child segregation of SNPs was also inves-
tigated for 43000 SNPs where one parent was homozygous
non-reference and the other homozygous reference (proband
expected to be heterozygous in 499% of cases) and
415 000 SNPs where both parents were homozygous non-ref-
erence (proband expected to be homozygous in 499% of
cases).
Kv3.3 (KCNC3) electrophysiological
analysis
To examine the functional effects of the T428I mutation in
the voltage-gated potassium channel Kv3.3, the coding region
of a sequence-veriﬁed human Kv3.3 (KCNC3) cDNA (Source
Bioscience) was subcloned into the pBF oocyte expression
vector prior to the introduction of the c.1283C4T mutation
by SPLICE-based site-directed mutagenesis (Davies et al.,
2007). Messenger RNA encoding either wild-type or mutant
Kv3.3 was then transcribed in vitro and injected into Xenopus
laevis oocytes for electrophysiological analysis using a stand-
ard two-electrode voltage clamp protocol as previously
described (D’Adamo et al., 1998; Imbrici et al., 2000, 2006).
Brieﬂy, whole-cell currents for either wild-type or mutant
channels were evoked by 200ms depolarizing commands to
+ 60mV from a holding potential of –80mV. For analysis of
the heterozygous state, oocytes were co-injected with wild-type
and T428I mutant mRNAs (1 ng wild-type and 1 ng T428I)
and compared with oocytes injected with either only wild-type
mRNA (2 ng) or T428I mutant mRNA (2ng). Data are
presented as the mean  SEM of 20–50 cells. Statistical
signiﬁcance was determined using an unpaired Student’s t-
test (**P50.001). Relative activation rates were recorded at
several voltages and ﬁtted with a single exponential function.
The relevant time constants were then calculated and plotted
as a function of the test pulse (data are presented as the
mean  SEM of eight cells). The structural homology model
of the fourth transmembrane segment (S4 voltage sensor
domain), showing the relative position of the T428I mutation
was created using the published crystal structure of the related
Kv1.2/KCNA2 (potassium voltage-gated channel subfamily A
member 2) channel as a template. Within this region, Kv1.2
exhibits 480% sequence identity with Kv3.3 (Long et al.,
2005).
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b-III spectrin (SPTBN2)
electrophysiology
Wild-type and R480W mutant rat b-III spectrin cDNA se-
quences were myc-tagged and cloned into the pRK5 mamma-
lian expression vector. The missense mutation was introduced
by site-directed mutagenesis using the pRK5-myc-tagged b-III
spectrin as template. Primary rat hippocampal neuronal cul-
tures were prepared from embryonic Day 18 Sprague-Dawley
embryos, transfected and current recordings made as previ-
ously described (Clarkson et al., 2014). Brieﬂy, cells were co-
transfected with constructs expressing wild-type b-III spectrin
and GFP or the R480W mutant and DsRed as it was previ-
ously shown that the different ﬂuorophores had no effect on
sodium currents when co-expressed or expressed alone
(Clarkson et al., 2014). Following transfection the cells were
mixed and plated together so that recordings could be made
from untransfected, wild-type b-III spectrin transfected and
R480W mutant transfected cells maintained under identical
culture conditions.
Results
Clinical summary
Cases 1–4 were diagnosed with ataxic cerebral palsy based
on standard criteria (Smithers-Sheedy et al., 2014), which
included the presence of an early ataxic motor disorder
with no clinical evidence of a neurodegenerative disorder.
All the children were born at term and there were no ob-
vious risk factors for cerebral palsy such as prematurity,
low birth weight, infections and hypoglycaemia. No other
identiﬁable causes were found, including neurometabolic
disorders. Having identiﬁed four cases with de novo muta-
tions we reviewed all the ataxia cases in our cohort and
identiﬁed six additional children who had congenital cere-
bellar ataxia and who had been analysed using exome
sequencing, but who did not have a speciﬁc diagnostic
label of ataxic cerebral palsy. Case 5 had no brain imaging
abnormalities and most closely resembles the other cases in
our series. Case 6 had cerebellar vermis hypoplasia and
Case 7 had global cerebellar hypoplasia (vermis and cere-
bellar hemispheres), both these cases were clinically stable.
Cases 8 and 9 developed clinical regression by the age of 5
and Case 10 had additional cataracts and an affected sib-
ling. Cases 8–10 would not fulﬁl the criteria for ataxic
cerebral palsy because of the clinical regression and syn-
dromic features and will be presented elsewhere. Table 1
summarizes the clinical details of Cases 1–7 and Fig. 1
shows brain imaging of Cases 2–4. The mutations identi-
ﬁed in Cases 1–4 were de novo, with parentage conﬁrmed
using SNP analysis (Fig. 2 and Supplementary Table 1).
Analysis of the raw exome data for Cases 2–4 did not
identify any low level somatic mosaicism of the mutant
alleles in either parent. No mutations have been found in
Cases 5 and 6 and a putative new gene had been found in
Case 7, which is currently under investigation and will be
presented elsewhere.
Case 1: T428I in KCNC3
Case 1 was reviewed locally in a specialist paediatric neu-
rodisability centre. He is the second child of healthy
non-consanguineous parents, with no family history of
neurological disorders. He was born at term, weighing
6 lbs 5 oz (2860 g), following an uneventful pregnancy
and normal vaginal delivery. He was noted to have early
motor delay of sitting, crawling and standing, associated
with some delay in cognitive abilities compared with his
peers. Investigations included creatine kinase, thyroid func-
tion tests, urinary amino and organic acids, chromosomes,
genetic testing for Fragile X syndrome and a brain MRI, all
of which were normal. After multiple paediatric neurology
reviews he was diagnosed as having ataxic cerebral palsy
and provided with intensive physiotherapy and occupa-
tional therapy support. Further developmental assessments
conﬁrmed both the motor abnormalities, with marked dis-
ability due to ataxia, in addition to some less prominent
cognitive difﬁculties requiring special support at school.
Non-verbal IQ testing gave a score of 90, on the low end
of the normal range.
Three non-synonymous changes were identiﬁed using tar-
geted capture and sequencing of 57 known ataxia genes. Of
these, only one, a previously unreported KCNC3 variant
c.1283C4T, p.T428I, was predicted to be functionally
damaging based on bioinformatic analysis including
amino acid conservation (Fig. 3A and Table 1). Bi-
directional Sanger sequencing conﬁrmed the next-genera-
tion sequencing ﬁndings (Fig. 3B) and analyses of other
rare SNPs in the proband and his parents were consistent
with the stated parentage (Fig. 2), conﬁrming that the mu-
tation arose de novo in the patient.
Mutations in KCNC3 have previously been reported to
underlie autosomal dominant spinocerebellar ataxia type
13 (SCA13) (Waters et al., 2006), although some variants
of uncertain pathogenic signiﬁcance have also been re-
ported (Figueroa et al., 2011). Therefore, we further inves-
tigated the pathogenicity of the T428I variant by
electrophysiological analysis of wild-type and mutant
Kv3.3 potassium channel currents expressed in a heterol-
ogous system.
The threonine residue at position 428 is a highly con-
served amino acid located at the base of the positively
charged S4 voltage-sensor helix of the Kv3.3 potassium
channel, a position that has previously been implicated in
the control of Kv channel activity (Fig. 3C) (Ledwell and
Aldrich, 1999; Pathak et al., 2005). Examination of the
functional properties of the T428I mutant channel in com-
parison with wild-type Kv3.3 clearly demonstrated that the
T428I mutant is non-functional (Fig. 4). Moreover, when
co-expressed with the wild-type subunit (to mimic the het-
erozygous state) the T428I mutation exerted a severe dom-
inant negative loss-of-function phenotype, reducing overall
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channel activity to below 50% of that seen with the wild-
type channel alone (Fig. 4B). Importantly, we also observed
that the remaining heteromeric channels displayed remark-
ably slower activation kinetics (Fig. 4C). These results
clearly demonstrate that the T428I mutation has a physio-
logically relevant damaging effect on Kv3.3 channel
function.
Case 2: N602D in ITPR1
Case 2 is the only child of non-consanguineous parents
who was born following difﬁculties with conception and
a single miscarriage. Birth weight was normal and head
circumference at birth on the 25th centile. The child was
noted to have delayed head control at 6 months, with head
nodding and rotatory nystagmus. The abnormal eye move-
ments and head nodding settled and subsequently delay
was noted in acquiring developmental milestones.
Multiple metabolic investigations were performed but no
cause was found. A brain MRI was normal (Fig. 1A). At
age 3 she was still not walking independently. Examination
revealed hypotonia and ataxia but no long-tract signs. Her
head circumference had dropped to the 3–10th centile. She
was socially very interactive and could use at least 15
words and will receive special educational support. At
almost 4 years old she is making good forward develop-
mental progress; clinical examination reveals ongoing
ataxia, she is able to weight-bear, but is not taking steps
and has mildly brisk reﬂexes with tight achilles tendons. In
this patient a de novo mutation c.1759A4G, p. N602D
was detected in ITPR1 (Fig. 5). Partial gene deletions (usu-
ally encompassing the 5’ region) of ITPR1 are known to
cause spinocerebellar ataxia type 15 (SCA15) (van de
Leemput et al., 2007) and more recently two missense mu-
tations, N602D and V1553M, were reported in two
families with autosomal dominant non-progressive cerebel-
lar ataxia (Huang et al., 2012). Residue N602 is located in
the IRBIT (IP3R Binding protein released with Inositol
1,4,5-Trisphosphate) binding domain of the ITPR1 gene
product, the IP3 receptor (IP3R), but little else is known
of how this missense mutation causes ataxia. IP3R is a re-
ceptor for inositol 1,4,5-trisphosphate (IP3), which is gen-
erated by the hydrolysis of the membrane lipid
phosphatidylinositol 4,5-bisphosphate (PIP2). IP3 binds to
the IP3R receptor, which is an intracellular ligand-gated
calcium ion (Ca2+ ) release channel localized in the endo-
plasmic reticulum. IP3Rs are involved in numerous pro-
cesses, such as dorsoventral axis formation, synaptic
plasticity, neural circuit formation and neuronal dendrite
formation (Mikoshiba et al., 1994; Mikoshiba, 2011;
Huang et al., 2012). IP3R is also modulated by a variety
of other proteins including IRBIT, which is a non-enzym-
atic homologue of S-adenosylhomocysteine hydrolase.
IRBIT modulates IP3R activation by competing with IP3
at the IP3 binding site, thereby reducing the receptor’s sen-
sitivity to IP3 and reducing Ca
2+ release (Ando et al.,
2006). The location of the N602D mutation, its evolution-
ary conservation (Table 1) and the previous report of an
identical mutation in an autosomal dominant cerebellar
ataxia family strongly support this mutation being
pathogenic.
Case 3: S1487D in ITPR1
Case 3 is the middle child of non-consanguineous parents;
the other two children are well. Pregnancy was notable for
an increased nuchal thickness, but amniocentesis revealed a
normal karyotype. He was born at term by normal vaginal
delivery and required no resuscitation. He sat at 12
months, crawled at 13–14 months and walked a few
steps before falling at 2 years 5 months. Height, weight
and head circumference were all on the 9th–25th centiles.
At 4 years he could walk unaided but continued to fall
frequently, he had shaky handwriting and could speak in
simple sentence structures but had good social interaction.
A brain MRI including the cerebellum was normal
(Fig. 1B). A complex deletion-insertion in ITPR1 was iden-
tiﬁed in this patient at nucleotides c.4459_4460delinsGA,
Figure 1 MRI of the brains of Cases 2, 3 and 4. (A and B) Cases 2 and 3 showing a normal brain MRI. (C) Case 4 brain MRI shows a small
cerebellum, with increased spacing of the cerebellar folia and an enlarged fourth ventricle. This was reported to be cerebellar atrophy, rather than
hypoplasia.
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Figure 2 Confirmation of parentage in Cases 1–4. (A) Sequences of rare SNPs in parents and affected of Case 1 showing consistency with
parentage: genes, variant and genomic location (hg19) are shown. (B) The non-reference discordance rate (NDR) over 86 000 exonic Hapmap
SNPs for Cases 2, 3 and 4. Related individuals show lower discordance (yellow) than unrelated individuals (blue/purple). This analysis confirms
that the probands in the study are genetically related to both parents and that parents are not genetically related to each other.
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resulting in a missense change p.S1487D. Both nucleotides
involved in the mutation are evolutionarily conserved and
S1487 is located at a highly conserved position in the CA8
(carbonic anhydrase related protein 8) binding domain of
ITPR1 (Hirota et al., 2003) (Fig. 5 and Table 1) suggesting
that this mutation is indeed pathogenic, although at this
stage it can only be classiﬁed as a ‘possible’ mutation.
Similar to IRBIT, CA8 is also a non-enzymatic competitor
of IP3 that binds to IP3R and interestingly, recessive muta-
tions in CA8 cause a congenital ataxia with intellectual
disability, possibly acting by disinhibiting the interaction
between IP3 and the IP3R, allowing extra Ca
2+ to be
released from IP3-sensitive stores (Turkmen et al., 2009;
Kaya et al., 2011)
Case 4: R480W in SPTBN2
Case 4 is the only child of non-consanguineous parents of
Mediterranean origin. She was born at term following a
normal pregnancy. Delivery was by induction and emer-
gency caesarean section for foetal distress, but she was
well following delivery and discharged home within a few
Figure 3 A novel de novo mutation predicted to affect the S4 voltage-sensor of Kv3.3. (A) The high degree of amino acid conser-
vation (asterisk) in the voltage-sensor S4 helix and S4-S4 linker region of human Kv3.3 and related species. This region is also highly conserved in
the paralogous channels KCNC1 (Kv3.1) and KCNC2 (Kv3.2). Threonine 428 in KCNC3 (Kv3.3) is highlighted in grey and is absolutely conserved
between species. (B) Sanger sequencing of the patient and parents to show that the heterozygous mutation is de novo. (C) A structural model of
this region in Kv3.3 with the predicted location of the T428I mutation. The conserved voltage-sensing arginine and lysine residues are also shown.
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days of birth. Within a few weeks she was noted to be head
nodding and had unsteady arm movements. An MRI per-
formed abroad was reported to show cerebellar hypoplasia.
At 8 months of age she had delayed development although
no evidence of regression and was able to sit unaided for
short periods. Detailed review at 20 months revealed a
normal head circumference, height and weight, although
the head circumference was on the 2–9th centile compared
to height and weight on the 50th centile, possibly indicating
mild relative microcephaly. She had an alternating conver-
gent squint with failure of abduction of the eyes on lateral
gaze, deep tendon reﬂexes were normal and plantars ﬂexor.
At 4 years and 10 months of age she was toileting with
assistance, had good social interaction with other children,
and better receptive than expressive language development.
Hearing is normal. Her squint is still present and she con-
tinues to be ataxic, being able to stand independently and
take a few steps aided. There is no evidence of spasticity or
dystonia, she has had no ﬁts, and continues to make for-
ward developmental progress. On this basis a working
diagnosis of ataxic cerebral palsy was made. A large set
of neurometabolic investigations including renal and liver
screen, -foetoprotein, creatine kinase, transferrin isolelec-
tophoresis, organic acids, very long chain fatty acids, white
cell enzymes, quantitative amino acids, and genetic tests
including array CGH, mitochondrial mutations, POLG,
Figure 4 The T428I mutation affects the functional properties of Kv3.3. (A) Representative current traces recorded from homomeric
wild-type (WT), homomeric mutant (T428I) and heteromeric (WT/T428I) Kv3.3 channels. The mutant channel exhibits a severe dominant-
negative, loss-of-function phenotype. (B) Quantifies this dominant negative effect in heteromeric (WT/T428I) channels that mimic the hetero-
zygous state. (C) Demonstrates that the residual current in the heterozygous state (WT/T428I) has markedly altered gating properties with much
slower rates of activation across a wide range of voltages. The inset panel compares representative traces for wild-type and heteromeric (WT/
T428I) channels recorded at + 60 mV.
Figure 5 Location of ITPR1 missense mutations in functional domains of the IP3R protein. De novo N587D and S1487N are
described in this paper. Inherited mutations (hash) are reported previously (Huang et al., 2012).
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Friedreichs ataxia, and PLA2G6 were normal. Brain MRI
was reported to show cerebellar atrophy (Fig. 1C). Exome
sequencing revealed a point mutation c.1438C4T,
p.R480W in SPTBN2 in this patient. The nucleotide is
conserved, as is the amino acid at this position (Table 1)
and the mutation is predicted as highly likely to be
damaging.
The same mutation has been reported in another spor-
adic case of early onset cerebellar ataxia with developmen-
tal delay; however in that case no segregation analysis was
performed, but the parents were unrelated to each other
and healthy, suggesting that the mutation may also have
arisen de novo (Jacob et al., 2013). This initial case report
did not provide any data on the pathogenicity of the mu-
tation, either from segregation or functional analysis. We
have previously shown that expression of wild-type bIII
spectrin (encoded by SPTBN2) can enhance voltage-gated
sodium channel currents in cultured hippocampal neurons
(Clarkson et al., 2014) in contrast to mutant b-III spectrin.
We therefore investigated the effect of this mutation on
voltage-gated sodium channel currents in cultured hippo-
campal neurons and show that sodium currents in the
presence of R480W bIII spectrin are lower compared to
wild-type bIII spectrin (Fig. 6) providing further evidence
for the pathogenicity of this mutation.
Discussion
This study is the ﬁrst to report de novo mutations in pa-
tients with a diagnostic label of cerebral palsy and has im-
portant implications for our understanding of this complex
condition. Although cerebral palsy is known to be an um-
brella diagnostic term with likely multiple causes, the aeti-
ology is often unknown. Our ﬁnding of de novo mutations
provides an explanation for many of the seemingly puzzling
features that have been described in the past including the
sporadic nature, the highly variable phenotype and the as-
sociation with increased paternal age (Fletcher and Foley,
1993).
From a clinical perspective, the diagnostic criteria for
cerebral palsy were recently and comprehensively reviewed
to assist clinicians. These include: a disorder of movement
or posture of central origin, a disorder of motor function,
no evidence of clinical regression, latest assessment at 4
years of age or older, absence of syndrome/brain anom-
aly/chromosomal anomaly and no evidence of generalized
hypotonia. If the patient fulﬁls these criteria and, in add-
ition, has ataxia then the diagnosis is ataxic cerebral palsy,
although the authors note that differentiating a neurode-
generative cerebellar ataxia can be difﬁcult and recommend
investigations to exclude this (Smithers-Sheedy et al., 2014).
Three of our cases clearly fulﬁlled the clinical criteria for
ataxia cerebral palsy as there was no clinical or imaging
evidence of regression and there were no syndromic fea-
tures. However, Case 4 illustrates the complexity of
making this diagnosis in young children when based on
clinical and radiological features. This patient was born
following an emergency Caesarian section for foetal distress
and in an era before imaging, the aetiology might have
been ascribed to ‘birth injury’. The clinical picture in this
case is of a stable cerebellar ataxia, rather than a neurode-
generative disorder and a diagnosis of ataxic cerebral palsy
falls within the current deﬁnition. Although the imaging
shows ‘cerebellar atrophy’ (deﬁned as a cerebellum with
initially normal structures in a posterior fossa of normal
size, which displays enlarged interfolial spaces in compari-
son with the foliae secondary to the loss of cerebellar
tissue) (Poretti et al., 2008) the lack of clinical regression
is not in keeping with a neurodegenerative disorder. Our
patient is still young but the previously reported case in the
literature reached 12 years of age without evidence of a
neurodegenerative disorder, suggesting that this is indeed
a clinically stable condition in childhood. Interestingly,
there are other cases in the literature with apparent cere-
bellar atrophy who do not have evidence of clinical regres-
sion either and in whom autosomal recessive genetic
mutations have been found (Yapici and Eraksoy, 2005;
Poretti et al., 2008; Burns et al., 2014). Case 4 certainly
warrants speciﬁc follow-up for evidence of clinical deteri-
oration and long-term follow-up in patients with these
newly deﬁned genetic disorders should greatly assist in
determining the prognosis. The difﬁculty of resolving the
apparent contradiction between a clinically stable disorder
with cerebellar imaging suggestive of atrophy is also illu-
strated in the case of ITPR1 mutations where there do not
appear to be consistent genotype–imaging correlations.
N602D in ITPR1 has been reported to cause cerebellar
hypoplasia and/or atrophy with long term clinical stability
(Huang et al., 2012) but the same de novo variant in our
Case 2 is associated with normal imaging.
The cases presented here also illustrate the overlap be-
tween the diagnostic categories of ataxic cerebral palsy and
non-progressive cerebellar ataxia. The latter group of dis-
orders was described in detail prior to the advent of next-
generation sequencing (Steinlin, 1998; Steinlin et al., 1998)
and include patients with or without cerebellar hypoplasia
(as deﬁned in Poretti et al., 2008). Therefore some of these
cases would also fulﬁl the criteria for a diagnosis of ataxic
cerebral palsy. The largest group of patients with non-
progressive cerebellar ataxia were those of unknown her-
edity and unknown aetiology (Steinlin, 1998). The clinical
features included early hypotonia and motor developmental
delay, with occasional spasticity and dystonia. The majority
had intellectual disability but the degree of the cognitive
impairment could not be predicted by the degree of
ataxia or the imaging ﬁndings.
A ﬁnding of speciﬁc interest is that nearly all of our pa-
tients also had some degree of intellectual disability. The
presence of intellectual disability in cerebral palsy is well
known and is estimated to be in the region of 35–50%,
therefore the ﬁnding of intellectual disability in the majority
of our cases of ataxic cerebral palsy is perhaps not surpris-
ing. However, there have been no previous reports
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speciﬁcally investigating the association of intellectual dis-
ability with ataxic cerebral palsy, and the rate of intellec-
tual disability is higher than might be expected from the
overall prevalence rate in cerebral palsy. Although the as-
sociation between congenital ataxia and intellectual disabil-
ity has not been emphasized in the literature, recently it has
been described in several cases of genetically conﬁrmed
congenital ataxia associated with cerebellar atrophy or
hypoplasia (Ozcelik et al., 2008; Turkmen et al., 2009;
Doi et al., 2011; Bourassa et al., 2012). The neural basis
underlying this observation remains uncertain. The concept
of the ‘cerebellar cognitive affective syndrome’ has been put
forward (Schmahmann and Sherman, 1997) and proposes
that the cerebellum has intrinsic cognitive functions.
However, in some genetic disorders there is evidence that
the genes responsible for cerebellar development are also
important in development of the cerebral cortex (and/or
hippocampus) (Lise et al., 2012). Further work is required
to elucidate the neural basis of this association.
The similarity in clinical phenotypes between our cases
suggests that there may be shared molecular mechanisms of
pathogenicity. In the case of KCNC3 and SPTBN2, we
have shown that the mutations behave as dominant
negatives and both of these affect channel function, directly
or indirectly. The mechanism of action of missense point
mutations in ITPR1 causing ataxia is unknown, but given
the effect of IP3R in modulating calcium release it is pos-
sible that these also cause dominant negative effects, which
further studies will need to elucidate. It is also possible that
these three genes affect converging cerebellar neurodevelop-
mental pathways (Marzban et al., 2014). Genes involved in
cerebellar development may also involve cerebral develop-
ment (Vieira et al., 2010; Martinez et al., 2013) and pro-
tein/regulatory networks involved in intellectual disability
have been identiﬁed in which there is an overlap with pro-
teins affecting cerebellar development (Najmabadi et al.,
2011). Whether this hypothesis can be extended to other
subtypes of cerebral palsy is unknown, although the ex-
tremely wide phenotypic spectrum of cerebral palsy sug-
gests that multiple genes and pathways are likely to be
involved.
The clinical phenotype of our patients is unusual for
many autosomal dominant spinocerebellar ataxias.
Mutations such as R420H in KCNC3 cause autosomal
dominant spinocerebellar ataxia, type 13 (SCA13) with a
late onset, progressive disorder. However, two other
Figure 6 Peak sodium current enhanced less by R480W than wild-type b-III spectrin. (A) Sodium current traces from representative
cells evoked with a series of 50 ms depolorizations from a holding potential of 90 mV to potentials ranging from 80 to + 20 mV in 10 mV
increments (stimulus protocol shown at bottom). (B) Sodium current peak at 10 mV normalized to control cells cultured at same time. (C)
Current-voltage relationships for control, wild-type (WT) and R480W with current amplitude normalized to peak value. All data are presented as
the mean  SEM (n = 5–9 cells from each of three independent cultures; P5 0.05).
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mutations in KCNC3, R423H and P448L do cause a very
rare non-progressive early onset autosomal dominant
ataxia that is sometimes associated with mild mental re-
tardation and normal imaging, reminiscent of our case
and also of the phenotype of ‘cerebral palsy’ (Waters
et al., 2006; Figueroa et al., 2010, 2011). It has been sug-
gested that the differences in phenotype are related to the
channel properties. The late onset R420H mutation pro-
duces a severe dominant negative effect with associated
loss of current amplitude, but has little effect on the
gating properties of the remaining heteromeric channels.
In contrast, the early onset R423H and P448L have dom-
inant negative effects which not only reduce overall current
levels, but also alter the properties of channel gating includ-
ing a hyperpolarized shift in the voltage dependence of ac-
tivation and slower activation kinetics; this is similar to the
effect we observe with the T428I mutation.
Dominant missense or in-frame mutations in SPTBN2
cause spinocerebellar ataxia type 5 (SCA5) a relatively
pure cerebellar disorder with little brainstem or spinocere-
bellar tract involvement. The disease onset is generally in
the third or fourth decade of life, although the age of onset
can be as young as 10 years of age and up to 68 years
(Bauer et al., 2006). Some juvenile-onset SCA5 patients
have bulbar and pyramidal tract dysfunction, in conjunc-
tion with a weakened ability to cough, which may shorten
lifespan (Ikeda et al., 2006). Cognitive impairment has not
been considered a prominent feature in autosomal domin-
ant SCA5. In contrast, autosomal recessive mutations in
SPTBN2 cause a congenital ataxia and cognitive impair-
ment with additional mild spasticity in the two families
reported to date (Lise et al., 2012; Elsayed et al., 2014).
In both families the mutations are stop codons with pre-
sumed loss of function of SPTBN2 in contrast to the dom-
inant negative effect demonstrated in SCA5 (Clarkson
et al., 2010). SPTBN2 encodes bIII spectrin, which is
involved in trafﬁcking and anchoring of crucial neurotrans-
mitter transporters and ion channels to the neuronal cell
membranes (Clarkson et al., 2010, 2014; Perkins et al.,
2010) and forms a heterotetramer with II spectrin. The
R480W mutation in SPTBN2 in Case 4 is located in the
second spectrin repeat, which is thought to be involved in
dimer formation prior to self association into the tetramer
and this mutation is therefore likely to have a signiﬁcant
impact on protein function. However, further investigation
is required to explain why this speciﬁc missense mutation
has such a severe phenotype compared with adult-onset
SCA5 cases.
Autosomal dominant spinocerebellar ataxia type 15 was
ﬁrst reported to be caused by gene deletions of ITPR1 (van
de Leemput et al., 2007). The mechanism of action has
been suggested to be haploinsufﬁciency, although this has
not been proven, and the mechanism of action in missense
mutations is unknown. The clinical phenotype in cases
involving deletions is of a slowly progressive gait and
limb ataxia, often in combination with ataxic dysarthria,
titubation, upper limb postural tremor, mild hyperreﬂexia,
gaze-evoked nystagmus, and impaired vestibulo-ocular
reﬂex gain. It is also generally considered to be an adult
onset disorder although onset at 7 years has been reported
(Storey, 1993). One family has been described with cogni-
tive decline (Castrioto et al., 2011). Missense mutations
have only recently been reported (Huang et al., 2012)
and the clinical phenotype in the father and daughter re-
ported in that paper is similar to our Case 2: the index case
had marked motor and speech delay with sitting at 8
months, only 10 words at 2 years, 4 months and develop-
ment of complex partial seizures at 5 years of age and the
father of the index case was reported to have had develop-
mental delay with independent walking from the age of 5
years and academic difﬁculties at school (Huang et al.,
2012). However, in contrast to our case with normal ima-
ging, the 1-year-old index case was described as having
cerebellar hypoplasia with subsequent atrophy by the age
of 5. Diffuse cerebellar atrophy was also found in the
father of the index case. The father was followed up until
aged 45 and there was no evidence of regression in either
case. As the mechanism of action is unknown, the explan-
ation for the progressive phenotype in the deletion cases
and an early onset but non-progressive disorder in the mis-
sense cases remains unknown.
The proportion of ataxic or other forms of cerebral palsy
that might be caused by de novo mutations is currently
unknown, but indirect evidence that this might be a
common mechanism includes a higher concordance of cere-
bral palsy in monozygotic than dizygotic twins, a higher
prevalence of congenital anomalies in cerebral palsy pa-
tients (which also can be caused by de novo mutations),
and the previously reported ﬁnding of increased paternal
age in dyskinetic cerebral palsy (Fletcher and Foley, 1993;
Fletcher and Marsden, 1996). A population-based study
estimated that 60% of hemiplegic cerebral palsy, 45% of
spastic diplegic, and 100% of isolated ataxic cerebral palsy
were caused by genetic mutations and interestingly, the
mathematical methodology used in the study has been pre-
viously validated and successfully applied to the study of
individuals with intellectual disabilities, which we now
know to be frequently caused by de novo mutations
(Costeff et al., 1983; Costeff, 2004; Gilissen et al., 2014).
A recent study of childhood ataxia has found that com-
pared with the overall prevalence of cerebral palsy (211/
100 000), ataxic cerebral palsy is uncommon (10/100 000)
but is one of the commonest types of ataxia in childhood
(26/100 000). In our modest cohort of 10 patients with
congenital ataxia, four had a clinical diagnosis of ataxic
cerebral palsy and an additional case (Case 5) was not
speciﬁcally diagnosed with this, but would fulﬁl all the
clinical and imaging criteria for this. Of these, four patients
had de novo mutations, and of the four patients who had a
normal scan (Cases 1–3, and 5), three had de novo
mutations.
The frequency with which genetic mutations might be
found in cerebral palsy partly depends on the diagnostic
terminology that is used. For example, exome sequencing
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has been reported in cases of ‘cerebral palsy-like encephal-
opathy’ or ‘masqueraders of cerebral palsy’ and although
most examples are autosomal recessive disorders a few de
novo mutations have been described (Rainier et al., 2006;
Lee et al., 2014; Srivastava et al., 2014; Yonekawa et al.,
2014). Some of these patients would not fulﬁl the strict
criteria for cerebral palsy but do reﬂect the challenges clin-
icians often face in ﬁnding an appropriate diagnostic term
for young children with highly variable clinical features of
unknown aetiology and with an unknown prognosis.
On average each person is thought to harbour 75 de
novo point mutations in their genome, but the majority are
in non-coding regions and are unlikely to have deleterious
functional consequences. In fact, on average, humans are
expected to have only one functionally signiﬁcant de novo
point mutation in the exome (Veltman and Brunner, 2012),
making the identiﬁcation of de novo mutations the most
likely cause of our patient’s motor and intellectual impair-
ments. However, the likelihood that de novo mutations are
disease-causing can only be determined when such genetic
changes are both bioinformatically and functionally tested
(Davies et al., 2012; Shanks et al., 2013b). Thus, we also
provide additional direct experimental evidence for the
pathogenicity of several of these mutations by electro-
physiological analysis of the mutant proteins. In Cases 1,
2 and 4 the combination of bioinformatics and electro-
physiology combined with previous reports provide com-
pelling evidence that these variants are pathogenic. In
Case 3, the de novo mutation has not previously been re-
ported. The evidence in favour of pathogenicity are that the
nucleotide conservation is high, it is predicted as deleterious
by SIFT and possibly damaging by PolyPhen-2, in common
with the other mutations reported here it is not present in
EVS, the variant is located in a functional domain and no
other possible variants were identiﬁed on exome sequen-
cing. Nevertheless, caution is necessary and at this stage
we would classify this as a possible mutation.
Cerebral palsy is a relatively common disorder, but de
novo mutations are rare genetic events. This paradox can
be explained by the reciprocal relationship between the size
of the ‘mutational target’ (i.e. the cumulative size of gene
loci in which a single large-effect mutation may cause the
phenotype) and the frequency of a disease caused by de
novo mutations (Veltman and Brunner, 2012). In the case
of cerebral palsy the ‘mutational target’ is likely to include
a huge number of neurodevelopmental genes in which in-
dividually rare single de novo mutations can lead to an
overall high frequency of cerebral palsy within the popula-
tion. The de novo origin of these cerebral palsy cases ex-
plains the lack of family history in parents or siblings and,
therefore, the lack of a readily apparent genetic cause. This
fact may also apply to other cases of cerebral palsy where
there are no obvious genetic risks and the risk to siblings of
the index case is comparatively low. Advanced paternal age
at conception is also associated with de novo mutations (de
Ligt et al., 2013) and the rate of paternal mutations is
estimated to increase by 4.28% per year, which
corresponds to doubling every 16.5 years and an increase
of two mutations per year (Kong et al., 2012). As much as
20 years ago it was proposed that sporadic cerebral palsy
could be associated with such a mechanism (Fletcher and
Foley, 1993) and it is therefore interesting to note that the
fathers of these four cases all ranged from 34–40 years old
at conception.
Our data suggest that cerebral palsy is on a diagnostic
and genetic continuum with intellectual disability, disorders
of motor development and possibly autistic spectrum dis-
order, with these latter conditions already known to be
caused by de novo mutations. Although, hypoxic ischaemic
encephalopathy is still likely to explain some cases of cere-
bral palsy, the identiﬁcation of genetic causes suggest that
this may be less frequent than previously thought. When
foetal monitoring was ﬁrst introduced hypoxic ischaemic
encephalopathy was considered to account for up to half
of cerebral palsy cases, but this was not supported by sub-
sequent studies and current evidence suggests that only 10–
15% of cerebral palsy is caused by birth asphyxia (Nelson,
1988; Graham et al., 2008). There are known risk factors
such as low birth weight, prematurity, maternal infections
and multiple gestations, but in these cases the cause is rela-
tively obvious. For example maternal fever in labour is
associated with an increased risk of cerebral palsy
(Grether and Nelson, 1997). However, in many cases,
including those presented here, no obvious risk factors
were identiﬁed and given the implications of this diagnosis
to an individual and family, searching for the causation
remains a priority. This suggests that great care should be
taken in using the term cerebral palsy without extensive
investigations to determine aetiology. Indeed in the genomic
era, being able to redeﬁne cases according to genetic caus-
ation may be extremely useful, allowing for better
classiﬁcations of cerebral palsy, which in turn should
assist management and understanding of prognosis. The
identiﬁcation of de novo mutations, which may only have
a modest effect on reproductive ﬁtness, also has important
implications for genetic counselling of patients, as the risk
to the offspring of such individuals will be 50%,
whereas the risk to the parents of having further affected
children is comparatively low and dependent on the (cur-
rently unknown) germline mosaicism rate. Even in cases
where there are obvious perinatal risk factors, an
underlying genetic mutation still may be present and a
thorough search for de novo mutations is now clearly war-
ranted before the cause can be ascribed to obstetric
misadventure.
The identiﬁcation of speciﬁc, proven pathogenic muta-
tions suggests that a useful way of investigating cerebral
palsy patients could be using family based whole-exome
or genome sequencing, which efﬁciently identiﬁes de novo
mutations in parents and child trio samples (de Ligt et al.,
2012, 2013). Exome and whole genome sequencing has
revolutionized our ability to investigate patients with rare
and complex conditions and its use in clinical practice has
been extensively reviewed (Miyatake and Matsumoto,
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2014; Schnekenberg and Nemeth, 2014). Although not yet
routinely available from all genetic services, there are in-
novative efforts to test the utility of whole genome sequen-
cing in clinical practice (e.g. http://www.genomicsengland.
co.uk/) and whole genome sequencing may yet uncover
additional types of de novo mutation. Our study has re-
ported point mutations that are comparatively straightfor-
ward to detect, but smaller copy number and structural
variants (which can be much harder to detect using stand-
ard technologies) also may be detectable using whole
genome sequencing as recently shown in intellectual disabil-
ity (Gilissen et al., 2014). Recent large scale studies have
particularly demonstrated its efﬁcacy for the identiﬁcation
of de novo mutations in developmental disorders that were
hitherto intractable using standard genetic investigations
(Wright et al., 2015).
In summary, we now provide the ﬁrst clear evidence that
some cases of ataxic cerebral palsy can be caused by
de novo point mutations and suggest that this ﬁnding
may be relevant to other subtypes of cerebral
palsy as well. The diagnostic overlap between ataxic cere-
bral palsy, non-progressive cerebellar ataxia and other con-
ditions such as intellectual disability and autistic
spectrum disorder raises important questions about the
use of the diagnostic term ‘cerebral palsy’, its relationship
to perinatal injury and the effect of presumed causation on
obstetric practice. Although further work is required to
expand the spectrum of mutations causing cerebral palsy,
our observations should prompt a major re-evaluation of
the aetiology and management of this devastating
condition.
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